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SUPPLEMENTARY NOTES
ABSTRACT
This is the Annual Summary of funding for this proposal. Human Protection Approval was received on 10/13/2009. This report covers the first 9 months of work for the study. Patients are being recruited and laboratory procedures are being established for the study according to the Statement of Work. 
SUBJECT TERMS
Brief Summary of SOW Tasks:
Task 1: (Specific Aim 1) Months 1-24 (Note: HRP Approval Granted 10/14/2010. We are in month 9 of the study) Fifty veterans with GWS who have fatigue and myalgias will be identified through the Atlanta Veterans Administration Medical Center and via website postings. Clinical records are requested and reviewed by the P. I. to confirm diagnosis of GWS. If the records are consistent with inclusion criteria, an appointment is made for clinical examination by the P.I., blood draw and skin biopsy. Modified criteria for chronic fatigue syndrome and fibromyalgia will be used as guides for patient inclusion criteria, thus allowing comparison of the GWS patient data with CFS/fibromyalgia patient data. Based on published percentages of study groups showing evidence for mitochondrial defects, we predict that approximately 60-70% of GWS patients will harbor mitochondrial defects.
Progress:
1. Five individuals are in the process of being recruited and entered into study. Records are being received and reviewed so that inclusion/exclusion criteria can be assessed. 2. Internet recruitment has been established 3. Notification/recruitment via patients at the Atlanta Veterans Administration Hospital has been established. We are notifying other Veteran Administration Hospitals so that they are aware of our study.
Task 2: (Specific Aim 2) Months 6-36 (Note: HRP Approval Granted 10/14/2010. We are in month 9 of the study) Characterize mitochondrial cellular energetics in GWS patients relative to age and gender matched controls using the following approaches: (1) high resolution respirometry of intact cells [EBV transformed lymphocytes, cultured fibroblasts], (2) quantitative analysis of individual mitochondrial proteins (denatured, Western blot), (3) analysis of intact OXPHOS enzyme complexes and supercomplexes (non-denatured, Blue Native and Clear Native gels), (4) in gel enzyme activity assessment of intact OXPHOS enzyme complexes and supercomplexes (Clear Native gel, in-gel activity measurements), (5) mtDNA copy number quantitation to assess for defects in regulating mtDNA replication, and (6) cellular coenzyme Q10 quantitation (endogenous synthesis is impaired in certain types of mitochondrial dysfunction).
1. All laboratory analyses are established in the laboratory for use in the study. Task 3: (Specific Aim 3) Months 6-36 (Note: HRP Approval Granted 10/14/2010. We are in month 9 of the study) Assess the mitochondrial DNA (mtDNA) from each patient with GWS for mtDNA mutations by whole genome sequencing of leukocyte and skin cell mtDNA. Based on the findings from Specific Aim II, selected nuclear coded OXPHOS genes will be sequenced to assess for mutations that increase susceptibility to GWS.
